TLR9 and head and neck squamous cell carcinoma: Combining anti-PD-1 with CMP-001 (a TLR-9 agonist) to treat head and neck squamous cell carcinoma (HNSCC) had a better effect and prolonged the survival time of mouse, compared with anti-PD-1 alone.